Deferasirox reduces serum ferritin and labile plasma iron in RBC transfusion-dependent patients with myelodysplastic syndrome

Journal of Clinical Oncology

Volumn 30, Issue 17, 2012, Pages 2134-2139

  List, Alan F ^a   Baer, Maria R ^b   Steensma, David P ^d   Raza, Azra ^c   Esposito, Jason ^e   Martinez Lopez, Noelia ^e   Paley, Carole ^e   Feigert, John ^f   Besa, Emmanuel ^g  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c Och Spine at New York Presbyterian Hospitals   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e NOVARTIS PHARMA AG   (Switzerland)

^f Fairfax Northern Virginia Hematology Oncology PC   (United States)

^g THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ALANINE AMINOTRANSFERASE; CREATININE; DEFERASIROX; DEFEROXAMINE MESYLATE; ERYTHROPOIETIN; FERRITIN; IRON; LENALIDOMIDE;

ABNORMAL LABORATORY RESULT; ADULT; AGED; ARTICLE; CREATININE BLOOD LEVEL; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; ERYTHROCYTE TRANSFUSION; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FERRITIN BLOOD LEVEL; FEVER; GASTROINTESTINAL SYMPTOM; GENE; GENE FREQUENCY; GENE MUTATION; HETEROZYGOTE; HFE GENE; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; IRON BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTOPENIA; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; BENZOIC ACIDS; ERYTHROCYTE TRANSFUSION; FEMALE; FERRITINS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IRON; IRON CHELATING AGENTS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MUTATION; MYELODYSPLASTIC SYNDROMES; PROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; TRIAZOLES;

EID: 84863900001     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.34.1222     Document Type: Article

References (24)

1. Brechignac S, Hellstrom-Lindberg E, Bowen DT, et al: Quality of life and economic impact of red blood cell (RBC) transfusions on patients with myelodysplastic syndromes (MDS). Blood 104:4716, 2004 (abstr)
2. Hellström-Lindberg E: Management of anemia associated with myelodysplastic syndrome. Semin Hematol 42:S10-S13, 2005 (suppl)
3. Delea TE, Hagiwara M, Phatak PD: Retrospective study of the association between transfusion frequency and potential complications of iron overload in patients with myelodysplastic syndrome and other acquired hematopoietic disorders. Curr Med Res Opin 25:139-147, 2009
4. Della Porta MG, Kuendgen A, Malcovati L, et al: Myelodysplastic syndrome (MDS)-specific comorbidity index for predicting the impact of extrahematological comorbidities on survival of patients with MDS. Blood 112:2677, 2008 (abstr)
5. Goldberg SL, Chen E, Corral M, et al: Influence of RBC transfusions on clinical outcomes among USA Medicare beneficiaries with newly diagnosed myelodysplastic syndromes. Leuk Res 33: S116, 2009 (suppl; abstr P099)
6. Jaeger M, Aul C, Sohngen D, et al: Iron overload in polytransfused patients with MDS: Use of L1 for oral iron chelation. Drugs Today 28:143-147, 1992 (suppl A) (Pubitemid 23038099)
7. Malcovati L, Della Porta MG, Pascutto C, et al: Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: A basis for clinical decision making. J Clin Oncol 23:7594-7603, 2005 (Pubitemid 46291823)
8. Rose C, Brechignac S, Vassilief D, et al: Positive impact of iron chelation therapy (CT) on survival in regularly transfused MDS patients: A prospective analysis by the GFM. Blood 110:249, 2007 (abstr)
9. Rose C, Brechignac S, Vassilief D, et al: Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myé-lodysplasies). Leuk Res 34:864-870, 2010
10. Chee CE, Steensma DP, Wu W, et al: Neither serum ferritin nor the number of red blood cell transfusions affect overall survival in refractory anemia with ringed sideroblasts. Am J Hematol 83:611-613, 2008
11. Patnaik MM, Lasho TL, Finke CM, et al: WHO-defined 'myelodysplastic syndrome with isolated del(5q)' in 88 consecutive patients: Survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations. Leukemia 24:1283-1289, 2010
12. Kohgo Y, Ikuta K, Ohtake T, et al: Body iron metabolism and pathophysiology of iron overload. Int J Hematol 88:7-15, 2008
13. Cabantchik ZI, Breuer W, Zanninelli G, et al: LPI-labile plasma iron in iron overload. Best Pract Res Clin Haematol 18:277-287, 2005 (Pubitemid 40298370)
14. Porter JB, Abeysinghe RD, Marshall L, et al: Kinetics of removal and reappearance of non-transferrin-bound plasma iron with deferoxamine therapy. Blood 88:705-713, 1996 (Pubitemid 26240403)
15. Messa E, Cilloni D, Messa F, et al: Deferasirox treatment improved the hemoglobin level and decreased transfusion requirements in four patients with the myelodysplastic syndrome and primary myelofibrosis. Acta Haematol 120:70-74, 2008
16. Jensen PD, Jensen IM, Ellegaard J: Desferrioxamine treatment reduces blood transfusion requirements in patients with myelodysplastic syndrome. Br J Haematol 80:121-124, 1992
17. Gattermann N, Schmid M, Della Porta M, et al: Efficacy and safety of deferasirox (Exjade) during 1 year of treatment in transfusion-dependent patients with myelodysplastic syndromes: Results from EPIC trial. Blood 112:633, 2008 (abstr)
18. Gattermann N, Finelli C, Porta MD, et al: Hematologic responses in myelodysplastic syndromes (MDS) patients treated with deferasirox: An EPIC post-hoc analysis using International Working Group (IWG) 2006 criteria. Blood 116:2912, 2010 (abstr)
19. Greenberg P, Cox C, LeBeau MM, et al: International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079-2088, 1997 (Pubitemid 27132124)
20. Cheson BD, Greenberg PL, Bennett JM, et al: Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 108:419-425, 2006 (Pubitemid 44061337)
21. Adams PC, Reboussin DM, Barton JC, et al: Hemochromatosis and iron-overload screening in a racially diverse population. N Engl J Med 352:1769-1778, 2005 (Pubitemid 40570925)
22. Gochee PA, Powell LW, Cullen DJ, et al: A population-based study of the biochemical and clinical expression of the H63D hemochromatosis mutation. Gastroenterology 122:646-651, 2002 (Pubitemid 34173816)
23. Olynyk JK, Cullen DJ, Aquilia S, et al: A population-based study of the clinical expression of the hemochromatosis gene. N Engl J Med 341:718-724, 1999 (Pubitemid 29407371)
24. Gattermann N, Finelli C, Porta MD, et al: Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study. Leuk Res 34:1143-1150, 2010